Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder
Status:
Completed
Trial end date:
2017-06-27
Target enrollment:
Participant gender:
Summary
The primary hypothesis is that compared to placebo, 10g of daily creatine monohydrate for
eight weeks will be associated with significant increases in frontal lobe phosphocreatine and
beta-nucleoside triphosphate (β-NTP) concentrations. A secondary hypothesis is that decreased
depressive symptoms measured with the Children's Depression Rating Scale-Revised (CDRS-R) and
Montgomery-Asberg Depression Rating Scale (MADRS) will be reciprocally correlated with
increased β-NTP concentrations.